Denali Therapeutics price target lowered to $80 from $87 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Denali Therapeutics (DNLI) to $80 from $87 and keeps a Buy rating on the shares. The firm says the results of the primary analysis of the Phase 1/2 study in Hunter syndrome continues to show “substantial and significant” reductions to normal and near-normal levels in central nervous system and peripheral biomarkers of disease.